Upper respiratory tract infection (URTI) in healthy, active people Respiratory
Conditions
Interventions
Prior to starting the study, all participants will be required to complete a health questionnaire to ensure they are suitable for participation. They will also be required to provide written informed
Sponsors
University of Kent
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. 18+ years old 2. Free from any injury or illness (no URTI within the last 4 weeks) 3. Deemed healthy via a pre-screening health questionnaire 4. No allergies or intolerances to dairy, pea or any other ingredients used in the investigational supplements
Exclusion criteria
Exclusion criteria: 1. Under 18 years old 2. Those with current injuries or illnesses (URTI within the last 4 weeks) 3. Those deemed not 'healthy' via a pre-screening health questionnaire 4. Those with allergies and/or intolerances to dairy, pea or any other ingredients used in the investigational supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of URTI episodes, recorded using the Jackson common cold questionnaire, completed daily during the 12 weeks and/or by swab-confirmed pathogen detection. | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 01/04/2025: Participants will visit the laboratory every four weeks (weeks 0, 4, 8 and 12): 1. URTI parameters (symptom duration; severity ratings) recorded using the Jackson common cold questionnaire, completed daily during the 12 weeks 2. URTI episodes with swab-confirmed pathogen detection: participants will be instructed to collect a “self-swab” if they experience a URTI episode (self-reported via Jackson questionnaire). Samples will be screened for the presence of known URTI-causing pathogens using a commercially available respiratory pathogen qPCR panel. 3. Measures of mucosal immunity (secretory IgA and antimicrobial peptides/proteins) will be determined by ELISA assays in saliva at rest on each laboratory visit. 4. Dairy lipid levels will be assessed by colorimetric coupled enzyme assay and/or NMR in blood samples obtained at rest on each laboratory visit. 5. Participants' overall well-being will be assessed using the Cohen-Hoberman Inventory of Physical Symptoms. Previous secondary outcome measures: Participants will visit the laboratory every four weeks (weeks 0, 4, 8 and 12): 1. URTI parameters (symptom duration; severity ratings) recorded using the Jackson common cold questionnaire, completed daily during the 12 weeks 2. URTI episodes with swab-confirmed pathogen detection: participants will be instructed to collect a “self-swab” if they experience a URTI episode (self-reported via Jackson questionnaire). Samples will be screened for the presence of known URTI-causing pathogens using a commercially available respiratory pathogen qPCR panel. 3. Immune cell function will be measured in immune cells in/from whole blood samples by emitted light analysis at rest on each laboratory visit. 4. Measures of mucosal immunity (secretory IgA and antimicrobial peptides/proteins) will be determined by ELISA assays in saliva at rest on each laboratory visit. 5. Stress hormone and cytokine levels will be measured by ELISA in bl | — |
Countries
England, United Kingdom
Contacts
Public ContactWilliam Searle
Outcome results
None listed